VALERIO TX (ALVIO.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALVIO - FR0010095596 - Common Stock
ALVIO.PA Key Statistics, Chart & Performance
The current stock price of ALVIO.PA is 0.155 EUR. In the past month the price decreased by -5.49%. In the past year, price increased by 103.95%.
ALVIO.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 66.13 | 43.32B | ||
| ARGX.BR | ARGENX SE | 65.51 | 42.91B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.53B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.59B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.74B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.86B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| NANO.PA | NANOBIOTIX | N/A | 841.84M | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| IVA.PA | INVENTIVA SA | N/A | 779.35M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About ALVIO.PA
Company Profile
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of oncology drugs targeting tumor intracellular processes. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
Company Info
VALERIO TX
49 boulevard du General Martial Valin
Paris ILE-DE-FRANCE FR
Employees: 38
Phone: 33145587600
VALERIO TX / ALVIO.PA FAQ
What does VALERIO TX do?
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of oncology drugs targeting tumor intracellular processes. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
What is the current price of ALVIO stock?
The current stock price of ALVIO.PA is 0.155 EUR. The price increased by 3.33% in the last trading session.
Does VALERIO TX pay dividends?
ALVIO.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALVIO stock?
ALVIO.PA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is ALVIO.PA stock listed?
ALVIO.PA stock is listed on the Euronext Paris exchange.
ALVIO.PA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ALVIO.PA. When comparing the yearly performance of all stocks, ALVIO.PA is one of the better performing stocks in the market, outperforming 99.05% of all stocks.
ALVIO.PA Financial Highlights
Over the last trailing twelve months ALVIO.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 29.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.61% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALVIO.PA Forecast & Estimates
7 analysts have analysed ALVIO.PA and the average price target is 0.01 EUR. This implies a price decrease of -93.42% is expected in the next year compared to the current price of 0.155.